UNLABELLED: Background : Cefepime was used as empirical treatment in ventilator-associated pneumonia (VAP) induced by gram-negative and gram-positive bacteria. This study aimed to determine the antimicrobial susceptibility pattern of cefepime against microorganism causing VAP in Mazandaran, North of Iran. METHODS: This study was performed on VAP patients diagnosed with clinical pulmonary infection score (CPIS) scores in ICU of two hospitals. For each patient suspected of having VAP, quantitative culture of endotracheal aspiration (QEA) was performed and MIC was determined by micro dilution test. Data were collected and analyzed. RESULTS: Thirty- five cases of enterobacteriaceae were isolated orderly including E coli 13, P. aeruginosa 11, Enterobacter 7 and K. pneumonia 4 cases. All the isolated E. coli, Enterobacter and Klebsiella, 54.5% of P. aeruginosa isolated were fully resistant to cefepime. CONCLUSION: The results of this study show that cefepime is not a reasonable choice for empirical treatment of nosocomial pneumonia and VAP.
UNLABELLED: Background : Cefepime was used as empirical treatment in ventilator-associated pneumonia (VAP) induced by gram-negative and gram-positive bacteria. This study aimed to determine the antimicrobial susceptibility pattern of cefepime against microorganism causing VAP in Mazandaran, North of Iran. METHODS: This study was performed on VAP patients diagnosed with clinical pulmonary infection score (CPIS) scores in ICU of two hospitals. For each patient suspected of having VAP, quantitative culture of endotracheal aspiration (QEA) was performed and MIC was determined by micro dilution test. Data were collected and analyzed. RESULTS: Thirty- five cases of enterobacteriaceae were isolated orderly including E coli 13, P. aeruginosa 11, Enterobacter 7 and K. pneumonia 4 cases. All the isolated E. coli, Enterobacter and Klebsiella, 54.5% of P. aeruginosa isolated were fully resistant to cefepime. CONCLUSION: The results of this study show that cefepime is not a reasonable choice for empirical treatment of nosocomial pneumonia and VAP.
Authors: S Aksaray; B DokuzoGuz; E Güvener; M Yücesoy; N Yuluğ; S Kocagöz; S Unal; S Cetin; S Calangu; M Günaydin; H Leblebicioğlu; S Esen; B Bayar; A Willke; D Findik; I Tuncer; B Baysal; F Günseren; L Mamikoğlu Journal: J Antimicrob Chemother Date: 2000-05 Impact factor: 5.790
Authors: D L Paterson; L Mulazimoglu; J M Casellas; W C Ko; H Goossens; A Von Gottberg; S Mohapatra; G M Trenholme; K P Klugman; J G McCormack; V L Yu Journal: Clin Infect Dis Date: 2000-03 Impact factor: 9.079
Authors: Joseph A Paladino; Jenna L Sunderlin; Mendel E Singer; Martin H Adelman; Jerome J Schentag Journal: Am J Health Syst Pharm Date: 2008-06-15 Impact factor: 2.637
Authors: B Georges; J-M Conil; T Seguin; E Dieye; P Cougot; J-F Decun; M Lavit; K Samii; G Houin; S Saivin Journal: Int J Clin Pharmacol Ther Date: 2008-04 Impact factor: 1.366